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Summary
The sarcoglycan sub-complex is a protein system which plays a key role in sarcolemma stabiliza-
tion during muscle activity. Although numerous studies have been conducted on this system, 
there are few data about its localization in non-muscular tissues. On this basis we carried out an 
indirect immunofluorescence study on normal rat cerebral and cerebellar cortex. In particular, 
we carried out single localization reactions to analyze if these proteins are present in brain and 
double localization reactions between sarcoglycans and either SMI-32 or GFAP to verify if they 
are expressed both in neurons and glial cells. We found that all tested sarcoglycans are present 
both in cerebral and cerebellar cortex and that they are expressed both in neurons and glial cells. 
The typical staining pattern of all sarcoglycans is represented by “spot-like” fluorescence, with 
spots of 0.5-2 μm average diameter laid out mainly around the soma of the cells. The main dif-
ference about sarcoglycans expression between cerebral and cerebellar cortex is that in the cer-
ebellar cortex the sarcoglycans positivity is detectable only in an area which is likely to corre-
spond to Purkinje cells layer. The presence of sarcoglycans in cerebral and cerebellar cortex and 
their disposition mainly around the soma of the cells suggest a role of these proteins in cellular 
signalling and in regulating postsynaptic receptor assembly mainly in axo-somatic synapses.
Key words
SMI-32; GFAP; brain; cerebellum; immunofluorescence; neurons; neuroglia.
Introduction
The sarcoglycan sub-complex (SGC) is a protein system made up of transmem-
brane glycoproteins which creates a connection between extracellular matrix compo-
nents and cytoskeleton; this protein system is a member of dystrophin glycoprotein 
complex which, besides sarcoglycans, contains the sarcoplasmic sub-complex, which 
includes dystrophin, dystrobrevin and syntrophins, and dystroglycan sub-complex 
which includes α- and β-dystroglycans.
The identification of sarcoglycans at first in muscle tissue suggests a key role of 
these proteins in sarcolemma stabilization during muscle activity (Revisit et al., 1990; 
Yoshida and Ozawa., 1990; Revisit and Campbell., 1991).
The SGC is made up of four transmembrane glycoproteins: one type I protein, 
α-sarcoglycan (50 kD), harbouring the N-terminal on the extracellular side, and three 
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type II proteins, β-, γ- and δ-sarcoglycans (43 kD, 35 kD and 35 kD, respectively), 
harbouring the N-terminal on the intracellular side (Yoshida et al., 1994). This sug-
gests that the sarcoglycans are divided in two different subunits: the first one, made 
up of α-sarcoglycan and the second one made up of β-, γ- and δ-sarcoglycans (Hack 
et al., 1998; Chan et al., 1998).
By molecular investigations, the way sarcoglycans link to each other to create the 
final complex has been studied. The results have shown that the assembly of the pro-
tein components starts from a central core, made up of β- and δ-sarcoglycans; after 
formation of β/δ-core, α- and γ-sarcoglycans determinate the maturation of the com-
plex and the link to dystrophin (Hack et al., 2000).
The SGC, similar to dystrophin, has also been extensively studied because of its 
involvement in some forms of hereditary muscular dystrophy, sarcoglycanophaty or 
Limb Girdle Muscular Dystrophy (LGMD) (Roberds et al., 1994; Bönnemann et al., 1995; 
Lim et al., 1995; Betto et al., 1999). The sarcoglycans have been mainly studied in skeletal 
and cardiac muscle where they show a costameric distribution (Anastasi et al., 2003).
A fifth sarcoglycan, ε-sarcoglycan, highly homologous to α-sarcoglycan, has been 
identified (Ettinger et al., 1997). The ε-sarcoglycan, because of its ubiquitous expres-
sion, is not considered muscle-specific (Ettinger et al., 1997; Chan et al., 1998; Duclos 
et al., 1998).
Since the identification of ε-sarcoglycan, the studies about these proteins have 
also been extended to smooth muscle fibres where it was hypothesized that the 
ε-sarcoglycan might replace α-sarcoglycan (Straub et al.,1999).
A novel mammalian sarcoglycan, ζ-sarcoglycan, with significant homologies to γ- 
and δ-sarcoglycan, has been identified (Wheeler et al., 2002).
The identification of this sixth sarcoglycan, ζ-sarcoglycan, suggests the exist-
ence of two different tetrameric complexes: the first one, made up of α-, β-, γ- and 
δ-sarcoglycan, characteristic of cardiac and skeletal muscle, and the second one, made 
up of β-, δ-, ε- and ζ-sarcoglycan, characteristic of smooth muscle (Straub et al., 1999; 
Wheeler et al., 2003).
In opposition to these results, a study carried out by immunofluorescence on 
smooth muscle has shown the expression of all five sarcoglycans, α-, β-, γ-, δ- and 
ε-sarcoglycans in this tissue (Anastasia et al., 2005). The presence of ζ-sarcoglycan 
was confirmed by molecular techniques. These results suggest the intriguing possibil-
ity of the existence of a pentameric - or hexameric considering ζ-sarcoglycan - SGC, 
with a higher or lower expression of individual sarcoglycans depending on muscle 
type (Anastasia et al., 2007).
The SGC, for its functional and structural role in stabilization of muscular fibres, 
was for long time studied only in muscular tissues. There are few data about sarco-
glycans in non-muscular tissues.
The study of sarcoglycans in non-muscular tissues has been mainly carried out on 
brain where recent researches have shown the importance of ε-sarcoglycan (DYT11) 
which, when mutated, determines Myoclonus Dystonia Syndrome (Zimprich et al., 
2001). In the cerebellum ε-sarcoglycan was found in the Purkinje cell and the molecu-
lar layers (Chan et al., 2005). In addition, the most recently described member of the 
sarcoglycan family, ζ-sarcoglycan, is also highly expressed in brain (Shiga et al., 2006).
 Therefore, on this basis, it is considered possible that the tetrameric ε-β-ζ-
δ-complex be present in the brain. This complex has already been described in 
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Schwann cells of peripheral nerves (Cai et al., 2007). However, although theoretically 
possible, the existence of a prototypical tetrameric sarcoglycan complex in the brain is 
considered unlikely (Waite et al., 2009).
Our recent studies on human brain biopsies, carried out by immunofluorescence, 
have demonstrated the expression of all five sarcoglycans, α-β-γ-δ-ε (unpublished 
data). On this basis, in this study we wanted to verify if all is forms of sarcoglycans 
are expressed in cerebral and cerebellar cortex of the rat.
Materials and methods
In the present study, five normal male Westar rats were used. The animals were 
sacrificed after anaesthesia and then their brains were extracted and fixed in 3% para-
formaldehyde in 0.2 mol/L phosphate buffer, pH 7.4. After numerous rinses in 0.2 
mol/L phosphate buffer and phosphate buffered saline 0.2 mol/L, pH 7.6 with 0.9% 
Nail (PBS), they were infiltrated with 12% and 18% sucrose and then both the cer-
ebrum and cerebellum were divided in two hemispheres.
The left hemisphere of cerebrum and cerebellum were frozen in liquid nitrogen 
and stored at -20° and reserved for sagittal cuts; the right hemispheres were sectioned 
by cryotomy, with coronal cuts in anterior to posterior direction, in 30 μm sections 
collected on glass slides coated with 0.5% gelatine and 0.005% chromium potassium 
sulphate. Three series of immunofluorescence reactions were performed: 1) single 
localization for α-, β-, γ-, δ-, and ε-sarcoglycans; 2) double localization between each 
sarcoglycans and SMI-32, a protein which marks a non-phosphorylated epitope of 
neurifilament proteins of neurons; 3) double localization between each sarcoglycans 
and GFAP, a protein which marks the glial fibrillary acidic protein of glial cells.
To block non-specific sites and to make membranes permeable, the sections were 
pre-incubated with 1% bovine serum albumin and 0.3% Triton X-100 in PBS at room 
temperature for 15 min and then with primary antibodies, at room temperature for 
2h. The following primary antibodies, obtained from Santa Cruz Biotechnology Inc. 
(CA, USA), were used: rabbit polyclonal anti-α-sarcoglycan (diluted 1:100); goat pol-
yclonal anti-β-sarcoglycans (diluted 1:100); goat polyclonal anti-γ-sarcoglycan (dilut-
ed 1:100); goat polyclonal anti-δ-sarcoglycan (diluted 1:100); goat polyclonal anti-ε-
sarcoglycan (diluted 1:100). Rabbit polyclonal anti-α-sarcoglycan antibody was dem-
onstrated with Texas Red-conjugated IgG anti rabbit (1:100 dilution; Jackson Immu-
noResearch Laboratories, West Grove, PA, USA) and goat polyclonal anti β-, γ-, δ-, 
and ε-sarcoglycans antibodies were demonstrated with Texas Red-conjugated IgG 
anti goat (1:100 dilution; Jackson ImmunoResearch Laboratories); secondary antibod-
ies were applied for 1 h at room temperature. For double localization reactions the 
sections were incubated also with the following primary antibodies, at room tem-
perature for 2h; mouse monoclonal anti SMI-32 RT (1:1000 dilution; Covance, Etery-
ville, CA, USA) and mouse monoclonal anti GFAP (Santa Cruz Biotechnology, Inc., 
CA, USA). Fluorescein isothiocyanate (FITC)-labelled anti mouse antibody (1:100 
dilution; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was used as 
secondary one for these antigens.
To label nuclei, after incubation with fluorochrome, the sections were incubat-
ed with DAPI (1:1000 dilution; Sigma Chemicals, St Louis, MO, USA) for 10 min. 
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Slides were finally washed in PBS and sealed with mounting medium. Samples were 
observed with a Zeiss LSM 510 confocal microscope equipped with Argon laser (458 
nm and 488 nm λ) and two HeNe laser (543 nm and 633 nm λ). All images were digi-
tized at a resolution of 8 bits into an array of 2048 x 2048 pixels. Optical sections of 
fluorescence specimens were obtained at 488 nm λ, at 62/s scanning speed with up 
to 8 repetitions on average. The pinhole size was set for optimal resolution. Contrast 
and brightness were established by examining the most brightly labelled pixels and 
choosing settings that allowed clear visualization of structural details while keeping 
the highest pixel intensities near 200. Digital images were cropped and figure mon-
tages were prepared using Adobe Photoshop 7.0.
Results
In order to verify the presence of sarcoglycans in cerebral and cerebellar cortex, 
single localization reactions for each sarcoglycans were performed. Observing cere-
bral cortex sections we found that a fluorescence pattern for α- (Fig. 1A), β- (Fig. 1B), 
γ- (Fig. 1C), δ- (Fig. 1D), ε-sarcoglycan (Fig. 1E) was detectable by red fluorescence. 
Moreover, at higher magnification, it was shown that the staining pattern of 
α-sarcoglycan (red channel), as all of other sarcoglycans (data not shown), appeared 
Figure 1 – Confocal image of rat cerebral cortex labelled with anti-α- (A), β- (B), γ- (C), δ- (D), and 
ε-sarcoglycans (E) (red channel) antibodies. The blue colour represents nuclear staining DAPI.
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as “spot-like” fluorescence, with spots about of 0.5-2 μ, which were distributed all 
around the soma of neurons(Fig. 2) whereas in glial cells the labelling was distributed 
in the central portion of the cell (Figs. 3B and 6B).
To understand which type of cerebral cells express sarcoglycans, we carried out 
double labelling reactions using antibodies against β-sarcoglycan and SMI-32 (red 
and green channel respectively in Fig. 3A), which marks the big pyramidal neurons, 
and with antibodies against δ-sarcoglycan and GFAP (red and green channel respec-
tively in Fig. 3B), which marks glial cells. SMI-32 and GFAP appeared also colocal-
ized with all other sarcoglycans (data not shown). These double localizations showed 
that each sarcoglycan is expressed both in neurons and glial cells where it is possible 
to observe colocalization represented by points of yellow fluorescence by merging red 
and green fluorescence (Fig. 3 A,B). 
Observing cerebellar cortex sections, we found labelling for α- (Fig. 4A), β- (Fig. 
4B), γ- (Fig. 4C), δ- (Fig. 4D), ε-sarcoglycan (Fig. 4E) also in this region. Moreover, the 
γ-sarcoglycan staining pattern was represented with a “spot-like” pattern similar to 
Figure 2 – Typical “spot-like” staining pattern of α-sarcoglycan (red channel) around the body of the cells, 
with spots about of 0.5-2 μ. The blue colour represents nuclear staining DAPI.
Figure 3 – Confocal image of rat cerebral cortex double-labelled with anti-β-sarcoglycan (red channel) and 
anti-SMI-32 (green channel) antibodies; the fluorescence appears as spot-like (A). Double-labelling with anti-
δ-sarcoglycan (red channel) and anti-GFAP (green channel) antibodies; the fluorescence is distributed in the 
central portion of the cell (B). 
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that of the cerebral cortex (Fig. 5); also all other sarcoglycan showed a similar staining 
pattern (data not shown).
The double localization reaction performed using antibodies against 
ε-sarcoglycan and SMI-32 (red and green channel respectively in Fig. 6A), and with 
antibodies against δ-sarcoglycan and GFAP (red and green channel respectively in 
Figure 4 – Confocal image of rat cerebellar cortex labelled with anti-α- (A), β- (B), γ- (C), δ- (D), and 
ε-sarcoglycans (E) (red channel) antibodies. Red fluorescence is distributed in a single cell layer.
Figure 5 – Typical “spot-like” staining pattern of γ-sarcoglycans (red channel) around the body of the cells, 
with spots about of 0.5-2 μ
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Fig. 6B), showed that the sarcoglycans are present both in cerebellar neurons and 
glial cells. SMI-32 and GFAP appeared also colocalized with all other sarcoglycans 
(data not shown). 
Sarcoglycan positivity in neurons of the cerebellar cortex was present mainly in 
an area likely corresponding to Purkinje cell layer (Fig. 4), while sarcoglycan positiv-
ity in neuronal cells of other regions of cerebellar cortex, like granular and molecular 
layers, was low or absent.
Discussion
Sarcoglycans are a group of proteins creating a connection between extracellular 
matrix and cytoskeleton. As well known, in skeletal muscle, this complex stabilizes 
the sarcolemma of myofibres protecting them from any possible damage provoked 
by continuing cycles of contraction and relaxation (Ervasti et al., 1990; Yoshida and 
Ozawa, 1990). Therefore, these proteins have been mainly studied on skeletal, car-
diac and smooth muscle fibres (Anastasi et al., 2004), but a few data are available 
about these proteins in non-muscular tissues. It has been demonstrated that α- and 
γ-sarcoglycans are specific of skeletal and cardiac muscle, whereas other sarcogly-
cans are more widely distributed (Roberds et al.,1993; Noguchi et al.,1995; Ettinger 
et al.,1997; McNally et al.,1998). Moreover, a mutation of ε-sarcoglycan is responsi-
ble of Myoclonus Dystonia Syndrome (Zimprich et al.2001), suggesting a key role of 
this protein in Central Nervous System (CNS); ζ-sarcoglycan was demonstrated to be 
also highly expressed in brain (Shiga et al., 2006), but there are no data about oth-
er sarcoglycans in CNS. It was instead described a complex made up of ε-, β-, δ-, 
and ζ-sarcoglycans in Schwann cells of peripheral nerve (Cai H. et al., 2007). The 
data of the present study have shown that in rat cerebral cortex: a) immunofluores-
cence for all tested sarcoglycans is detectable in all observed regions; b) sarcogly-
Figure 6 – Confocal image of rat cerebellar cortex double-labelled with anti-ε-sarcoglycan (red channel) and 
anti-SMI-32 (green channel) antibodies; the fluorescence appears as spot-like (A). Double-labelling with anti-
δ-sarcoglycan (red channel) and anti-GFAP (green channel) antibodies; the fluorescence is distributed in the 
central portion of the cell (B).
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cans are present both in neurons and glial cells; c) the staining pattern for all sarco-
glycans is “spot-like” around the soma of neurons while in glial cells the labelling 
is found in the central portion of the cells. In opposition to a report which consid-
ered only ε- and ζ-sarcoglycans to be present in brain (Waite et al., 2009), our results 
show that in rat brain α-, β-, γ-, and δ-sarcoglycans are present too, independently of 
the species, since we have already demonstrated the expression of α-, β-, γ-, δ- and 
ε-sarcoglycans in human intra-surgical brain biopsies by immunofluorescence tech-
niques (unpublished data). On this basis we can hypothesize that in brain an hexa-
meric SGC-like exists, similar to pentameric/hexameric SGC described in muscular 
tissue (Anastasi et al., 2007), but plays a different role if compared with muscle fibres. 
Sarcoglycans, in the cerebral cortex, appears as intermittent spots about of 0.5-2 μm , 
mainly around the soma of the neurons. These results suggest that sarcoglycans may 
play a key role in cellular signalling, regulating membrane synaptic receptors assem-
bly. In particular, the predominant presence of spots around the soma indicate that 
sarcoglycans may regulate membrane post-synaptic receptors assembly mainly in 
axosomatic synapses. Moreover it was demonstrated that ε-sarcoglycan is present in 
many brain regions and that it is associated with dopaminergic neurons (Nishiyama 
et al., 2004; Chan et al., 2005); preliminary neurochemical analysis of ε-sarcoglycan-
deficient mice have shown increased levels of dopamine and its metabolites within 
the striatum (Yokoi et al., 2006). Thus, ε-sarcoglycan may be involved in dopamin-
ergic neurotransmission (Waite et al., 2009). Besides, it was hypothesized that Dys-
trophin and the Dystrophin-Glycoprotein Complex (DGC) is involved in modulating 
synapse function at a subset of GABAergic synapses in the hippocampus and cere-
bellum (Levi et al., 2002; Kush et al., 2008). On this basis we can speculate that the 
presence of sarcoglycans around the soma of neurons may marks a specific subset 
of postsynaptic receptors. Sarcoglycans have been previously studied in Schwann 
cells of peripheral nervous system were it was demonstrated that they are involved 
in myelin stabilization (Cai et al., 2007); moreover, it was demonstrated a role of dys-
trophin-glycoprotein complex of glial cells in the maintenance of the brain-blood-bar-
rier (Haenggi and Fritschy, 2006). Therefore, we can hypothesize that in the glial cells 
of cerebral cortex these protein may play a role as membrane receptors involved in 
myelin stabilization and in the maintenance of the brain-blood-barrier. In rat cerebel-
lar cortex: a) all tested sarcoglycans are present; b) sarcoglycans present a spot-like 
staining pattern mainly around the soma of neurons; c) the sarcoglycan positivity in 
neurons is detectable mainly in an area which is likely to correspond to Purkinje cell 
layer, with a low or absent positivity in neurons present in molecular and granular 
layers; d) sarcoglycans are also expressed in glial cells where their labelling is distrib-
uted in a central portion of the cell. Chan et al. (2005) had demonstrated the presence 
of only ε-sarcoglycan in mouse brain. Our results show that all sarcoglycans are pre-
sent also in cerebellum cortex of the rat. Sarcoglycan positivity is detectable mainly 
in a type of neurons, the Purkinje cells. In fact, our results show a low or absent sar-
coglycans fluorescence in granular and molecular layers. Moreover, the presence of 
a sarcoglycans “spot like” staining pattern around the soma of the cells suggest that, 
also in cerebellum cortex, sarcoglycans might be associated with specific postsynap-
tic receptors of Purkinje cells. Therefore sarcoglycans may play an important role in 
Purkinje cell layer, independent of the species. In glial cells of cerebellum cortex sar-
coglycans may play the same role which we have hypothesized for them in cerebral 
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cortex glial cells.
In conclusion, our results shows that α-, β-, γ-, δ- and ε-sarcoglycans are 
expressed in rat cerebral and cerebellar cortex, where we suppose that they are 
involved in specific synaptic neurotransmission. These preliminary results could 
open a new research line concerning the study of sarcoglycans in non-muscular tis-
sues, demonstrating again that these proteins are not muscle-specific; moreover, the 
information about the presence of sarcoglycans in cerebral and cerebellar cortex, pro-
vided by this study, might give birth to further researches. It is interesting to investi-
gate other parts of normal and pathological brain to define a possible involvement of 
these proteins in modulating synaptic neurotransmission.
References
Anastasi G., Amato A., Tarone G., Vita G., Monici M.C., Magaudda L., Brancaccio M., 
Sidoti A., Trimarchi F., Favaloro A., Cutroneo G. (2003) Distribution and localiza-
tion of vinculin-talin-integrin system and dystrophin-glycoprotein complex in 
human skeletal muscle. Cells Tissues Organs 175: 151-164.
Anastasi G., Cutroneo G., Trimarchi F., Rizzo G., Bramanti P., Bruschetta D., Fugaz-
zotto D., Cinelli M.P., Soscia A., Santoro G., Favaloro A. (2003) Sarcoglycans 
in human skeletal muscle and human cardiac muscle: a confocal laser scanning 
microscope study. Cells Tissues Organs 173: 54-63.
Anastasi G., Cutroneo G., Rizzo G., Arco A., Santoro G., Bramanti P., Vitetta A.G., 
Pisani A., Trimarchi F., Favaloro A. (2004) Sarcoglycan and integrin localization in 
normal human skeletal muscle: a confocal laser scanning microscope study. Eur. J. 
Histochem. 48: 245-252.
Anastasi G., Cutroneo G., Sidoti A., Santoro G., D’Angelo R., Rizzo G., Rinaldi C., 
Giacobbe O., Bramanti P., Navarra G., Amato A., Favaloro A. (2005) Sarcogly-
can subcomplex in normal human smooth muscle: an immunohistochemical and 
molecular study. Int. J. Mol. Med. 16: 367-374.
Anastasi G., Cutroneo G., Sidoti A., Rinaldi C., Bruschetta D., Rizzo G., D’Angelo R., 
Tarone G., Amato A., Favaloro A. (2007) Sarcoglycan subcomplex expression in 
normal human smooth muscle. J. Histochem. Cytochem. 55: 831-843.
Betto R., Biral D., Sandonà D. (1999) Functional roles of dystrophin and associated 
proteins. New insights for the sarcoglycans. Ital. J. Neurol. Sci. 20: 371-379. 
Bönnemann C.G., Modi R., Noguchi S., Mizuno Y., Yoshida M., Gussoni E., McNally 
E.M., Duggan D.J., Angelini C., Hoffman E.P. (1995) Beta-sarcoglycan (A3b) muta-
tions cause autosomal recessive muscular dystrophy with loss of the sarcoglycan 
complex. Nat. Genet. 11: 266-273.
Cai H., Erdman R.A., Zweier L., Chen J., Shaw J.H. 4th, Baylor K.A., Stecker M.M., 
Carey D.J., Chan Y.M. (2007) The sarcoglycan complex in Schwann and its role in 
myelin stability. J. Neuropathol. Exp. Neurol. 205: 257-269.
Chan Y.M., Bönnemann C.G., Lidov H.G., Kunkel L.M. (1998) Molecular organization 
of sarcoglycan complex in mouse myotubes in culture. J. Cell Biol. 143: 2033-2044.
Chan P., Gonzalez-Maeso J., Ruf F., Bishop D.F., Hof P.R., Sealfon SC. (2005) Epsilon-
sarcoglycan immunoreactivity and mRNA expression in mouse brain. J. Comp. 
Neurol. 482: 50-73.
63Sarcoglycans in cerebral and cerebellar cortex
Duclos F., Straub V., Moore S.A., Venzke D.P., Hrstka R.F., Crosbie R.H., Durbeej 
M., Lebakken C.S., Ettinger A.J., van der Meulen J., Holt K.H., Lim L.E., Sanes 
J.R., Davidson B.L., Faulkner J.A., Williamson R., Campbell K.P. (1998) Progres-
sive muscular dystrophy in alpha-sarcoglycan-deficient mice. J. Cell. Biol. 142: 
1461-1471.
Ervasti J.M., Ohlendieck K., Kahl S.D., Gaver M.G., Campbell K.P. (1990) Deficiency 
of a glycoprotein component of the dystrophin complex in dystrophic muscle. 
Nature 345: 315-319.
Ervasti J.M., Campbell K.P. (1991) Membrane organization of the dystrophin-glyco-
protein complex. Cell 66: 1121-1131.
Ettinger A.J., Feng G., Sanes J.R. (1997) ipsilon-Sarcoglycan, a broadly expressed hom-
ologue of the gene mutated in limb-girdle muscular dystrophy 2D. J. Biol. Chem. 
272: 32534-32538.
Hack A.A., Ly C.T., Jiang F., Clendenin C.J., Sigrist K.S., Wollmann R.L., McNally 
E.M. (1998) Gamma-sarcoglycan deficiency leads to muscle membrane defects and 
apopotosis independent od dystrophin. J. Cell Biol. 142: 1279-1287.
Hack A.A., Lam M.Y., Cordier L., Shoturma D.I., Ly C.T., Hadhazy M.A., Hadhazy 
M.R., Sweeney H.L., McNally E.M. (2000) Differential requirement for individual 
sarcoglycans and dystrophin in the assembly and function of the dystrophin-gly-
coprotein complex. J. Cell Sci. 113: 2535-2544.
Haenggi T., Fritschy J.M. (2006) Role of dystrophin and utrophin for assembly and 
function of the dystrophin glycoprotein complex in non-muscle tissue. Cell. Mol. 
Life Sci. 63: 1614-1631.
Kueh S.L, Head S.I., Morley J.W. (2008) GABA(A) receptor expression and inhibito-
ry post-synaptic currents in cerebellar Purkinje cells in dystrophin-deficient Mdx 
mice. Clin. Exp. Pharmacol. Physiol. 35: 207-210.
Lim L.E., Duclos F., Broux O., Bourg N., Sunada Y., Allamand V., Meyer J., Richard I., 
Moomaw C., Slaughter C., Tomè F.M.S., Fardeau M., Jackson C.E., Beckmann J.S 
and Campbell K.P. (1995) Beta-sarcoglycan: characterization and role in limb-girdle 
muscular dystrophy linked to 4q12. Nat. Genet. 11: 257-265.
Lévi S., Grady R.M., Henry M.D., Campbell K.P., Sanes J.R., Craig A.M. (2002) Dys-
troglycan is selectively associated with inhibitory GABAergic synapses but is dis-
pensable for their differentiation. J. Neurosci. 22: 4274-4285.
McNally E.M., Ly C.T., Kunkel L.M. (1998) Human epsilon-sarcoglycan is highly 
related to alpha-sarcoglycan (adhalin), the limb girdle muscular dystrophy 2D 
gene. FEBS Lett. 422: 27-32.
Noguchi S., McNally E.M., Ben Othmane K., Hagiwara Y., Mizuno Y., Yoshida M., 
Yamamoto H., Bönnemann C.G., Gussoni E., Denton P.H., Kyriakides T., Middle-
ton L., Hentati F., Ben Hamida M., Nonaka I., Vance J.M., Kunkel L.M., Ozawa E. 
(1995) Mutations in the dystrophin-associated protein gamma-sarcoglycan in chro-
mosome 13 muscular dystrophy. Science 270: 819-822.
Nishiyama A., Endo T., Takeda S., Imamura M. (2004) Identification and characteriza-
tion of epsilon-sarcoglycans in the central nervous system. Brain Res. Mol. Brain 
Res. 125: 1-12.
Roberds S.L., Anderson R.D., Ibraghimov-Beskrovnaya O., Campbell K.P. (1993) Pri-
mary structure and muscle-specific expression of the 50-kDa dystrophin-associat-
ed glycoprotein (adhalin). J. Biol. Chem. 268: 23739-23742.
64 Giovanna Vermiglio, Michele Runci, Antonino Scibilia, et al.
Roberds S.L, Leturcq F., Allamand V., Piccolo F., Jeanpierre M., Anderson R.D., Lim 
L.E., Lee J.C., Tomè F.M.S., Romero N.B., Fardeau M., Beckmann J.S., Kaplan J.C. 
and Campbell K.P. (1994) Missense mutations in the adhalin gene linked to auto-
somal recessive muscular dystrophy. Cell 78: 625-633.
Straub V., Ettinger A.J., Durbeej M., Venzke D.P., Cutshall S., Sanes J.R., Campbell K.P. 
(1999) Epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a 
unique dystrophin-glycoprotein complex. J. Biol. Chem. 274: 27989-27996.
Shiga K., Yoshioka H., Matsumiya T., Kimura I., Takeda S., Imamura M. (2006) Zeta-
sarcoglycan is a functional homologue of gamma-sarcoglycan in the formation of 
the sarcoglycan complex. Exp. Cell Res. 312: 2083-2092.
Waite A., Tinsley C.L., Locke M., Blake D.J. (2009) The neurobiology of the dystro-
phin-associated glycoprotein complex. Ann. Med. 41: 344-359.
Wheeler M.T., Zarnegar S., McNally E.M. (2002) Zeta-sarcoglycan, a novel component 
of the sarcoglycan complex, is reduced in muscular dystrophy. Hum. Mol. Genet. 
11: 2147-2154.
Wheeler M.T., McNally E.M. (2003) Sarcoglycans in vascular smooth and striated 
muscle. Trends Cardiovasc. Med. 13: 238-243.
Yokoi F., Dang M.T., Li J., Li Y. (2006) Myoclonus, motor deficits, alterations in emo-
tional responses and monoamine metabolism in epsilon-sarcoglycan deficient 
mice. J. Biochem. 140: 141-146.
Yoshida M., Ozawa E. (1990) Glycoprotein complex anchoring dystrophin to sarco-
lemma. J. Biochem. 108: 748-752.
Yoshida M., Suzuki A., Yamamoto H., Noguchi S., Mizuno Y., Ozawa E. (1994) Dis-
sociation of the complex of dystrophin and its associated proteins into several 
unique groups by n-octyl β-D-glucoside. Eur. J. Biochem. 222: 1055-1061. 
Zimprich A., Grabowski M., Asmus F., Naumann M., Berg D., Bertram M., Scheidt-
mann K., Kern P., Winkelmann J., Müller-Myhsok B., Riedel L., Bauer M., Mül-
ler T., Castro M., Meitinger T., Strom T.M., Gasser T. (2001) Mutations in the gene 
encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat. Genet. 
29: 66-69.
